I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EL/982743214 U.S. in an envelope addressed to: MS AF, Commissioner for Patents, P.O. Box 1450, Alexandra IVA 22513-1450, on the date shown below.

Dated: November 3, 2004 Signatu

Docket No.: UMY-052

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re Patent Application of:

Craig C. Mello et al.

Application No.: 09/689992

Confirmation No.: 1020

Filed: October 13, 2000

Art Unit: 1637

For: RNA INTERFERENCE PATHWAY GENES

AS TOOLS FOR TARGETED GENETIC

INTERFERENCE

Examiner: Teresa E. Strzelecka

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATION CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

MS AF Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

The U.S. Patent and Trademark Office has taken the position that the previous "Sequence Listing" in computer readable form did not comply with the requirements of Section 1.824 for the stated reason that it contained several raw sequence listing errors. Submitted herewith in connection with the above-referenced patent application is a substitute, computer readable copy of the Sequence Listing that corrects the defects noted in the raw sequence listing. No new matter has been added to the substitute Sequence Listing.

Applicants respectfully request the above-referenced patent application be placed upon the files for examination.

Application No.: 09/689992 Docket No.: UMY-052

Applicant believes no fee is due with this statement. However, if a fee is due, please charge our Deposit Account No. 12-0080, under Order No. UMY-052 from which the undersigned is authorized to draw.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 12-0080, under Order No. UMY-052.

Dated: November 3, 2004

Respectfully submitted,

Debra J. Milasincic, Esq.

Registration No.: 46,931

LAHIVE & COCKFIELD, LLP 28 State Street

Boston, Massachusetts 02109

(617) 227-7400

(617) 742-4214 (Fax)

Attorney/Agent For Applicant

	and the second	A Commence of the Commence of	
01163	Application No.	Applicant(s)	
NOV 0 3 2004 7	09/689,992	MELLO ET AL.	
Notice to Comply	Examiner	Art Unit	
TRADEMAR!	Teresa E Strzelecka	1637	
NOTICE TO COMPLY WITH REQUIREMENT NUCLEOTIDE SEQUENCE AND/OR AMIN			
Applicant must file the items indicated below within the avoid abandonment under 35 U.S.C. § 133 (extension)			
The nucleotide and/or amino acid sequence disclosu for such a disclosure as set forth in 37 C.F.R. 1.821 -			nents
1. This application clearly fails to comply with the directed to the final rulemaking notice published the effective filing date is on or after July 1, 1998, 1998) and 1211 OG 82 (June 23, 1998).	at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990).	
2. This application does not contain, as a separate required by 37 C.F.R. 1.821(c).	te part of the disclosure on pa	aper copy, a "Sequence Listing" as	
3. A copy of the "Sequence Listing" in computer of 37 C.F.R. 1.821(e).	readable form has not been s	submitted as required by	
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."			
5. The computer readable form that has been file unreadable as indicated on the attached CRF Dissubmitted as required by 37 C.F.R. 1.825(d).			st be
☐ 6. The paper copy of the "Sequence Listing" is no as required by 37 C.F.R. 1.821(e).	ot the same as the computer	readable from of the "Sequence Listi	ing"
☐ 7. Other:			
Applicant Must Provide: ☑ An initial or substitute computer readable form (C	CRF) copy of the "Sequence I	_isting".	
☐ An initial or substitute paper copy of the "Sequen specification.	ce Listing", as well as an am	endment directing its entry into the	
☑ A statement that the content of the paper and content on new matter, as required by 37 C.F.R. 1.821(e) or			clude

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216 For CRF Submission Help, call (703) 308-4212 PatentIn Software Program Support

Technical Assistance......703-287-0200

To Purchase Patentin Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY